Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Progyny, Inc. (PGNY) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Progyny (PGNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Progyny (PGNY) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.15 per share a year ago.

Progyny (PGNY) Beats Q2 Earnings Estimates

Achieves Record Quarterly Adjusted EBITDA, Strong Cash Flow Conversion RateBoard Authorizes Repurchase of $100 Million of Common Stock

Progyny, Inc. Announces Second Quarter 2024 Results

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth

NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended June 30, 2024 after the close of the market on Tuesday, August 6, 2024.

Progyny, Inc. Announces Details for Its Second Quarter 2024 Results Report

The Alabama court ruling had a lingering impact on Progyny in Q1 as the company missed revenue targets and adjusted their 2024 growth outlook downward. Progyny recently acquired Berlin-based Apryl, which should help the company gain exposure internationally. Listed by Time Magazine as one of the top 100 most influential companies of 2024, Progyny is still a dominant leader in a growing niche market.

Progyny: Recent Stock Decline Provides Buying Opportunity

Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Assisted Reproductive Technology Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering. The global assisted reproductive technology market reached a value of nearly $37.6 billion in 2023, having grown at a compound annual growth rate (CAGR) of 5.6% since 2018. The market is expected to grow from $37.6 billion in 2023 to $55.91 billion in 2028 at a rate of 8.3%. The market is then expected to grow at a CAGR of 8.4% from 2028 and reach $83.8 billion in 2033.

Assisted Reproductive Technology Market Report 2024-2033: Vitrolife Leads the Competition with 9.8% Share, Followed by Ferring, and Progyny

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that it will host its inaugural Investor Day in New York City on Monday, August 12, 2024, from 9:00 A.M. Eastern Time until approximately 1:00 P.M. Eastern Time.

Progyny, Inc. to Host 2024 Inaugural Investor Day

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny's guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care.

Progyny, Inc. Announces Enhanced Global Services with Acquisition of Apryl

Kindbody is the Largest Women-founded, Women-led Fertility Company Serving Employers and Families through its National Clinic Network and Proprietary Technology Platform NEW YORK, June 11, 2024 /PRNewswire/ -- Kindbody , the leading national fertility clinic network and global family-building benefits provider for employers, today announced its Founder and Executive Chairman, Gina Bartasi, will return as the company's CEO during a time of unprecedented growth. The Company recently shared that it expected to deliver revenue in the range of $225-$250 million for 2024 and is now profitable after years of significant investment into new clinic locations and proprietary technology.

Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth

Progyny finds itself in an industry enjoying numerous secular tailwinds that they are well-positioned to capitalize on. The company reported Q1'24 on the 9th of May, with the stock plummeting around 15% after reporting a revenue miss. This presents an attractive entry point, with a conservatively estimated 49-76% upside.

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 9:00 A.M. Eastern Time.

Progyny, Inc. to Present at Jefferies Global Healthcare Conference

PGNY experienced a revenue miss in 1Q24 due to weak utilization. Historical data shows that IVF demand has been resilient, with strong rebounds following economic downturns. Leading indicators suggest that utilization rates are already improving, and demand remains solid, indicating potential for growth acceleration in the coming quarters.

Progyny: No Change To Long-Term Outlook

The board of Progyny PGNY, -2.62% has approved a $100 million share-repurchase authorization, its second this year.

Progyny's board approves another $100 million stock buyback

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100 million of its common stock. This follows the program that was previously announced on February 29, 2024. The program will be funded through available cash balances.

Progyny, Inc. Announces Additional Share Repurchase Program

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Progyny's executives will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 5:00 P.M. Pacific Time / 8:00 P.M. Eastern Time. They will also participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference 2024 on Wednesday, May 29, 2024, at 1:00 P.M. Central Time / 2:00 P.M. Eastern Time.

Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024

Shares of Progyny Inc. were headed for a record selloff Friday after the fertility-services company said the Supreme Court of Alabama's February ruling regarding in vitro fertilization seemed to scare off some potential customers.

Progyny's stock plunges as demand for IVF treatments drops after Alabama ruling

Progyny (NASDAQ: PGNY ) stock is falling hard on Friday after the fertility and family-building benefits solutions company announced earnings results for its first quarter of 2024. The bad news for PGNY investors starts with its revenue of $278.08 million during the quarter.

Why Is Progyny (PGNY) Stock Down 27% Today?

Progyny, Inc. (NASDAQ:PGNY ) Q1 2024 Earnings Conference Call May 9, 2024 4:45 PM ET Company Participants James Hart – Investor Relations Pete Anevski – Chief Executive Officer Mark Livingston – Chief Financial Officer Michael Sturmer – President Conference Call Participants Anne Samuel – JPMorgan Michael Cherny – Leerink Glen Santangelo – Jefferies Jailendra Singh – Truist Sarah James – Cantor Fitzgerald Scott Schoenhaus – KeyBanc Stephanie Davis – Barclays Richard Close – Canaccord Genuity David Larson – BTIG Allen Lutz – Bank of America Operator Good day, everyone, and welcome to the Progyny, Inc. First Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.

Progyny, Inc. (PGNY) Q1 2024 Earnings Call Transcript

Early Sales Activity and New Partnerships Provide Strong Start to Selling Season, Affirming Continued Demand for Fertility and Family Building Solutions Early Sales Activity and New Partnerships Provide Strong Start to Selling Season, Affirming Continued Demand for Fertility and Family Building Solutions

Progyny, Inc. Announces First Quarter 2024 Results

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended March 31, 2024 after the close of the market on Thursday, May 9, 2024.

Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report

The organizations will host an event with Canada's leading providers, employers, and fertility advocates to show support for the millions in need of family building care The organizations will host an event with Canada's leading providers, employers, and fertility advocates to show support for the millions in need of family building care

Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care

Addus HomeCare

Catalyst Pharmaceuticals

Integer Holdings

Owens & Minor

CNBC's Jim Cramer said he thinks it could be a good year for small cap stocks and shared his top picks.

Jim Cramer recommends five small-cap health-care stocks

The leading benefits solution and largest infertility advocacy non-profit will host a series of events aimed at raising awareness for the millions of individuals facing family building challenges The leading benefits solution and largest infertility advocacy non-profit will host a series of events aimed at raising awareness for the millions of individuals facing family building challenges

News for Progyny Stock (PGNY)